Oncolytic Virotherapy Targeting the IL15 Pathway
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Emens L, Molinero L, Loi S, Rugo H, Schneeweiss A, Dieras V
. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. J Natl Cancer Inst. 2021; 113(8):1005-1016.
PMC: 8328980.
DOI: 10.1093/jnci/djab004.
View
2.
Dubois S, Mariner J, Waldmann T, Tagaya Y
. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity. 2002; 17(5):537-47.
DOI: 10.1016/s1074-7613(02)00429-6.
View
3.
Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C
. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383(23):2207-2218.
DOI: 10.1056/NEJMoa2017699.
View
4.
Rhode P, Egan J, Xu W, Hong H, Webb G, Chen X
. Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models. Cancer Immunol Res. 2015; 4(1):49-60.
PMC: 4703482.
DOI: 10.1158/2326-6066.CIR-15-0093-T.
View
5.
Ylosmaki E, Cerullo V
. Design and application of oncolytic viruses for cancer immunotherapy. Curr Opin Biotechnol. 2019; 65:25-36.
DOI: 10.1016/j.copbio.2019.11.016.
View